End-of-life care intensity among adolescent and young adult patients with cancer in Kaiser Permanente Southern California
A partir des données d'un registre américain des cancers portant sur 663 patients adolescents et jeunes adultes atteints d'un cancer de stade avancé, cette étude analyse les conditions et l'intensité des soins de fin de vie (âge lors du décès : 15-39 ans)
Importance : Cancer is the leading disease-related cause of death among adolescents and young adults (AYAs), but little is known about the care that AYA patients with cancer receive at the end of life (EOL).
Objective To evaluate the intensity of EOL care among AYA patients with cancer.
Design, Setting, and Participants : Cross-sectional study of Kaiser Permanente Southern California (KSPC) cancer registry data and electronic health records for 663 AYA patients with either stage I to III cancer and evidence of cancer recurrence or stage IV cancer at diagnosis. All patients were treated within KSPC, an integrated health care delivery system, and died between 2001 and 2010 before age 40 years (age range at time of death, 15-39 years).
Main Outcomes and Measures : (1) Chemotherapy use in the last 14 days of life; (2) intensive care unit (ICU) care in the last 30 days of life; (3) more than 1 emergency department (ED) visit in the last 30 days of life; (4) hospitalization in the last 30 days of life; and (5) a composite measure of medically intensive EOL care including any of the aforementioned measures.Results Eleven percent of patients (72 of 663) received chemotherapy within 14 days of death. In the last 30 days of life, 22% of patients (144 of 663) were admitted to the ICU; 22% (147 of 663) had more than 1 ED visit; and 62% (413 of 663) were hospitalized. Overall, 68% of patients (449 of 663) received at least 1 medically intensive EOL care measure.
Conclusions and Relevance : Most AYA patients received at least 1 form of medically intensive EOL care. These findings suggest the need to better understand EOL care preferences and decision making in this young population.
JAMA Oncology , résumé, 2014